BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant
(HSCT) and receiving preparative chemotherapy experience a considerable amount of
chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this
patient population are suboptimal due to lack of efficacy and supportive evidence, potential
for increased adverse events, and drug-drug and drug-disease contraindications.